Satnam Surae

Chief Product Officer at Aigenpulse    


Satnam has been active in the Life Sciences for more than 10 years. While originally focussing on Biochemistry, he discovered early on his passion for applying information technologies to biological challenges. His unique ability to transition between both worlds enables our teams to effectively develop the product and at the same time provides him with the ability to shape our customer engagement.

Contributing Author   in
Tools & Methods  

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Articles from Satnam

Pharma’s Data Dilemma: How Machine-Learning Tools Hold the Key to Unlocking Novel Insights

   2814
Pharma’s Data Dilemma: How Machine-Learning Tools Hold the Key to Unlocking Novel Insights

Covid-19 is still having a devastating effect on many countries and economies worldwide and has brought to light the impact of diseases that affect some people in worse ways than others. With SARS-CoV-2, ethnicity, gender, age, and underlying health conditions all play a part in disease severity and mortality, but there is mounting evidence to suggest that the status of the immune system early after infection can be predictive of those who go on to have the worst symptoms. The scale and threat of the pandemic has led to the need for rapid analysis of the disease – because the better we understand it, the more easily we can help healthcare professionals to make critical personalised treatment decisions. Advanced technologies such as artificial intelligence and machine learning are playing a large role in this process, and with other diseases, too, accelerating scientific research to enable major breakthroughs.